ArticleActa Cardiologica Sinica2020
Impact of Apelin-13 on the Development of Coronary Artery Ectasia.
Article in Acta Cardiologica Sinica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Apelin and its ratio to lipid factors are associated with cardiovascular diseases: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Apelin-13 as a novel diagnostic laboratory biomarker in thromboembolic disorders: a review of literature with prospective insights.International journal of emergency medicine · 2024Review
- Circulating Myokines as Novel Biomarkers for Cardiovascular Diseases.Reviews in cardiovascular medicine · 2024Review
- Renin-Angiotensin System Inhibitors and COVID-19: Potential Therapeutics Rather Than Perpetrators.Acta Cardiologica Sinica · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronary artery ectasia (CAE) is the limitation or diffuse expansion of the epicardial coronary artery. In most cases, the pathological basis of CAE is considered to be coronary atherosclerosis. Previous studies have confirmed the association between Apelin and arterial atherosclerosis. Apelin-13 (AP-13) is the main serum Apelin subtype in healthy humans, however the effect of serum AP-13 on CAE has yet to be elucidated. In this research, we analysed the relationship between serum AP-13 levels and CAE.
methodsOne hundred and forty subjects who underwent selective diagnostic coronary angiography were enrolled in this research. We identified and included 40 patients with CAE as the study subjects. Another 50 patients with coronary artery disease (CAD) were randomly selected as the CAD group, and 50 patients without CAD were selected as the normal control group. Serum AP-13 levels were collected for all subjects.
resultsThere were no statistically significant differences in baseline data except for gender. After unconditional logistic regression analysis, AP-13 and HDL-c were independent risk factors for CAE (both p < 0.05). The serum AP-13 level was significantly lower in the CAE patients than in the CAD patients (1.86 ± 0.59 vs. 2.49 ± 1.19 ng/mL, p = 0.004). Serum AP-13 levels were slightly lower in the CAD patients than in the controls (2.49 ± 1.19 vs. 3.12 ± 1.64, p = 0.079).
conclusionsApelin-13 may have an effect on the development of CAE. Further studies should be performed to elucidate the possible pathogenic role of AP-13 in CAE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.